### 1 PERMISSIVE OMICRON BREAKTHROUGH INFECTIONS IN INDIVIDUALS WITH BINDING OR

### 2 NEUTRALIZING ANTIBODIES TO ANCESTRAL SARS-CoV-2

- 3 Erin Williams<sup>1,3</sup>, Jordan Colson<sup>4</sup>, Ranjini Valiathan<sup>4</sup>, Juan Manuel Carreño<sup>6,8</sup>, Florian Krammer<sup>6,7,8</sup>, Michael
- 4 Hoffer<sup>1,5</sup>, Suresh Pallikkuth<sup>2</sup>, Savita Pahwa<sup>2\*</sup>, David Andrews<sup>4\*</sup>
- <sup>1</sup> Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136
- 6 USA
- 7 <sup>2</sup> Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami,
- 8 Florida, 33146, USA
- <sup>3</sup> Department of Biomedical Engineering, University of Miami, Miami, Florida, 33136, USA
- 10 <sup>4</sup> Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine,
- 11 Miami, Florida, 33136, USA
- 12 <sup>5</sup> Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida,
- 13 33136, USA
- <sup>6</sup> Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029,
- 15 USA
- 16 <sup>7</sup> Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount
- 17 Sinai, New York, New York, 10029, USA
- 18 <sup>8</sup> Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at
- 19 Mount Sinai, New York, NY, USA
- 20

### 21 Corresponding authors:

- 22 David Andrews, M.D. at the Department of Pathology, University of Miami Miller School of Medicine,
- 23 Department of Pathology and Laboratory Medicine, JMH Holtz 2026, 1611 NW 12 Avenue, Miami, FL
- 24 33136, USA

- 25 Phone: 305-585-5886
- 26 Fax: 304-243-2013
- 27 Email: <u>dandrews@miami.edu</u>

- 29 Savita Pahwa, M.D. at the Department of Microbiology and Immunology (Pediatrics and Medicine),
- 30 University of Miami Miller School of Medicine, 1580 NW 10th Avenue; BCRI 712, Miami, FL 33136, USA
- **31** Phone: 305-243-7732
- 32 Fax: 305-243-7211
- 33 Email: <u>spahwa@med.miami.edu</u>
- 34
- 35
- 36

### 37 ABSTRACT

- 38 Background
- 39 Breakthrough infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
- 40 variant (B.1.1.529) has occurred in populations with high vaccination rates. These infections are due to
- 41 sequence variation in the spike protein leading to a reduction in protection afforded by the current
- 42 vaccines, which are based on the original Wuhan-Hu-1 strain, or by natural infection with pre-Omicron
- 43 strains.
- 44
- 45 Methods
- 46 In a longitudinal cohort study, pre-breakthrough infection sera for Omicron breakthroughs (n=12) were
- 47 analyzed. Assays utilized include a laboratory-developed solid phase binding assay to recombinant spike
- 48 protein, a commercial assay to the S1 domain of the spike protein calibrated to the World Health
- 49 Organization (WHO) standard, and a commercial solid-phase surrogate neutralizing activity (SNA) assay.
- 50 All assays employed spike protein preparations based on sequences from the Wuhan-Hu-1 strain.
- 51 Participant demographics and clinical characteristics were captured.
- 52
- 53 Results
- 54 Pre-breakthrough binding antibody (bAB) titers ranged from 1:800-1:51,200 for the laboratory-
- 55 developed binding assay, which correlated well and agreed quantitatively with the commercial spike S1
- 56 domain WHO calibrated assay. SNA was detected in 10/12 (83%) samples.

57

- 58 Conclusions
- 59 Neither high bAB nor SNA were markers of protection from Omicron infection/re-infection. Laboratory
- 60 tests with antigen targets based on Wuhan-Hu-1 may not accurately reflect the degree of immune

- 61 protection from variants with significant spike protein differences. Omicron breakthrough infections are
- 62 likely due to high sequence variation of the spike protein and reflect incomplete immune protection
- 63 from previous infection with strains that preceded Omicron or with vaccinations based on the original
- 64 Wuhan-Hu-1 strain.

### 65 INTRODUCTION

66	First reported in November 2021, the Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2 progressed
67	rapidly to become the predominant strain in the United States, comprising 99.5% of all new infections
68	[1] in mid-December 2021. The Omicron variant is notable for its high transmissibility within the
69	population with pre-existing immunity, as well as significant antigenic differences in the spike protein
70	compared to the original Wuhan-Hu-1 strain as well as variants like Alpha, Beta, Gamma and Delta [2].
71	The Omicron spike (S) glycoprotein, which is responsible for initiating viral entry into cells [3], contains
72	at least 32 amino acid changes [4] compared to the Wuhan-Hu-1 strain, with mutations spanning the
73	receptor binding domain (RBD) and N-terminal domain (NTD) and the furin cleavage site (FCS).
74	
75	Most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines currently available are
76	based on spike protein sequences derived from the Wuhan-Hu-1 strain. Consequently, as variant SARS-
77	CoV-2 strains have emerged with altered spike protein sequences (compared to the Wuhan-Hu-1 strain),
78	reduced antibody binding titers and reduced viral neutralizing activities have been observed [5]. Recent
79	work has shown that a reduction in antibodies with spike binding and viral neutralizing activity [6-10] are
80	associated with an increased risk of infection in fully vaccinated individuals, including those who were
81	previously infected.
82	
83	Along with nucleic acid and antigen testing, antibody testing has been widely utilized in research,
84	epidemiological and clinical settings during the coronavirus disease 2019 (COVID-19) pandemic, with
85	over 85 tests commercially available under US FDA Emergency Use Authorization to date [11]. The
86	majority of the antibody detection methods employ solid phase binding assays such as enzyme linked
87	immunosorbent assays (ELISA), with some capable of detecting surrogate neutralizing antibody activity

88 [12]. Unfortunately, the role of antibodies as correlates of protection, while well established in general

89 [13-16], has been complicated by the lack of standardization for US serology assays and the emergence90 of variants [17].

91

112

92	Antibody reactivity to recombinant spike proteins has been widely used as a marker for humoral
93	immunity [16, 18-20], particularly in the context of the recent Delta and Omicron waves, both associated
94	with breakthrough infections worldwide. Several groups have reported the use of binding or viral
95	neutralizing antibody titers as correlates of protection against SARS-CoV-2 [16]. Similarly, there is
96	evidence to support an association between lower viral neutralizing antibody titers and breakthrough
97	infections [17, 21, 22], though a specific threshold for risk reduction or protection has not been well
98	established. Increased viral neutralizing activity has also been observed following booster vaccination
99	[23, 24], with associated reduced disease severity and rates of hospitalization, in comparison with
100	individuals who did not receive booster doses.
101	
102	Here, we investigate binding antibody titers and receptor binding domain (RBD)-angiotensin converting
103	enzyme 2 (ACE2) interaction inhibiting antibody activity among previously vaccinated patients
104	presenting with presumptive Omicron breakthrough infection. Our study compares three antibody tests:
105	a two-step quantitative IgG binding assay to the full spike ectodomain (Icahn School of Medicine at
106	Mount Sinai assay), a semi-quantitative assay for total serum immunoglobulins inhibiting RBD-ACE2
107	interactions (GenScript cPass)[25], and a quantitative binding titer assay for IgG to S1 domain (Ortho
108	Clinical Diagnostics VITROS)[26], which is the only commercial antibody assay calibrated to the WHO
109	standard in the United States. The primary aim of this work is to investigate the impact of binding
110	antibody titers and RBD-ACE2 interaction inhibition titers on Omicron breakthrough infections. We also
111	aim to assess the limitations of the three clinically available laboratory tools in the context of Omicron

6

variant infection, which is known to have significant properties of immune escape.

113

### 114 METHODS

- **115** *Study Design and Participants*
- 116 We included 12 study participants who are enrolled in our IRB-approved (#20201026), ongoing,
- 117 longitudinal SARS-CoV-2 immunity study ("CITY") at the University of Miami Miller School of Medicine.
- 118 Following written informed consent, participants answered a demographic and health history
- 119 questionnaire. Nasal swab samples (Ruhof, Mineola, NY) were collected at each visit to screen for active
- 120 SARS-CoV-2 infection and whole blood samples (Becton Dickinson, Franklin Lakes, NJ) were drawn for
- serum before storage at -80°C. All participants agreed to sample banking and consented to their use in
- 122 future research. Any individual (12/186 active participants [6.5%]) who self-reported breakthrough
- 123 infection between December 15<sup>th</sup>, 2021, and January 7<sup>th</sup>, 2022, was included in this study. They were
- 124 polled for additional information regarding their breakthrough infection, including associated
- 125 symptoms.
- 126
- 127 *Omicron Breakthroughs*

Previously vaccinated individuals who experienced breakthrough infection between December 15<sup>th</sup>, 2021, and January 7<sup>th</sup>, 2022, were included in this study (n=12). These dates corresponded with the national surge associated with high (>98%) Omicron variant infection prevalence. Breakthrough infections were established with a clinically validated positive nucleic acid amplification test (NAAT) method, such as PCR (polymerase chain reaction). Serum samples obtained at the study visit prior to breakthrough infection were retrieved from storage for the individuals described above.

134

135 Assays

136 - Mount Sinai Laboratory assay

137	The SARS-CoV-2 ELISAs were performed using a well-described two step assay developed by the Icahn
138	School of Medicine at Mount Sinai [27-29]. Briefly, 96-well plates were coated at 4°C with SARS-CoV-2
139	spike protein (2 $\mu$ g/ml) solution and incubated overnight. Plates were blocked with 3% non-fat milk
140	prepared in PBS with 0.1% Tween 20 (PBST) and incubated at room temperature for 1h. After blocking,
141	serial dilutions of heat inactivated serum samples were added to the plates and incubated for 2h at
142	room temperature. Plates were washed three times with 0.1% PBST followed by addition of a 1:3,000
143	dilution of goat anti-human IgG–horseradish peroxidase (HRP) conjugated secondary antibody (50 $\mu$ l)
144	well and incubated 1h. Plates were washed, 100 $\mu$ l SIGMAFAST OPD (o-phenylenediamine
145	dihydrochloride;) solution was added to each well for 10 min and then the reaction was stopped by the
146	addition of $50\mu$ l per well of 3M hydrochloric acid. The optical density at 490nm (OD490) was measured
147	using a Synergy 4 (BioTek) plate reader. The background value was set at an OD490 of 0.15 then discrete
148	titers were reported in values of 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 1:25600,
149	1:51200, 1:102400, and 1:204800. The limit of detection was set at 1:100.
150	
151	- Genscript cPass <sup>™</sup> surrogate neutralization antibody assay
152	This semi-quantitative SARS-CoV-2 surrogate neutralizing antibody assay, which measures the inhibition
153	of RBD and ACE2 interactions, was performed in accordance with manufacturer's instructions. In brief,
154	participant serum was mixed with dilution buffer and soluble RBD-HRP conjugate. After a 30-minute
155	incubation at 37 °C, samples were added to a 96-well plate which was pre-coated with recombinant
156	human ACE2 protein. The plate was incubated for 15 min at 37 °C, sample mixture removed, wells were
157	washed, substrate added, and plates were read at 450nm on a Dynex (Dynex Technologies, Chantilly,
158	VA) Agility multiplate ELISA instrument. Data was reported as percent neutralization with a threshold of

159 30% as the cutoff for surrogate neutralizing activity. Values from 30-100% surrogate neutralizing activity

160 were considered positive and values below 30% were considered negative for surrogate neutralizing

161 activity.

162

- 163 Ortho Clinical VITROS SARS-CoV-2 lgG assay
- 164 This assay was performed following the manufacturer's instructions on an Ortho-Clinical VITROS 7600
- analyzer (Ortho Clinical Diagnostics, Raritan, NJ). This assay is calibrated to the 1<sup>st</sup> WHO International
- 166 Standard Anti-SARS-CoV02 Immunoglobulin (Human), NIBSC [26] with results reported in the WHO
- 167 standard units of IgG Binding Antibody Units/ml (BAU/ml) to recombinant spike S1 domain. The assay
- 168 measurement range is 2.0 200 BAU/ml. Participant serum was diluted with manufacturer diluent to
- achieve a measurable result within the manufacturer measurement range, followed by conversion of
- the result with the dilution factor to achieve the final BAU/ml concentration.
- 171
- 172 Statistical analysis
- 173 Following log-transformation, Pearson correlation coefficients and Bland-Altman plots were generated
- in order to examine the correlation and degree of agreement between the Mount Sinai Laboratory assay

and Ortho-Clinical VITROS assay. All statistical analyses and figures generated were performed in R

176 Studio.

177

#### 178 RESULTS

**179** *Patient characteristics* 

180 As shown in Table 2, the gender distribution was equal with a median age of 50.5 (range: 30-78). Six

- 181 (50%) entered the study with a previous history of COVID-19, confirmed via documented NAAT testing.
- 182 The participants most commonly identified as White (83.3%) and non-Hispanic (66.6%). None were
- 183 known to be immunocompromised. All had received primary vaccination greater than 90 days prior to

184	breakthrough, to include Pfizer/BioNTech BNT162b2 (66.7%), Moderna mRNA-1273(25%), and Johnson
185	& Johnson Ad26.COV2.S (8.3%). Among those patients who had not yet received a booster (n=5), two
186	reported a history of previous COVID-19 at study entry. Also of note, the one individual who received
187	the Johnson & Johnson vaccine had been previously infected with SARS-CoV-2 twice prior to vaccine
188	receipt. Seven received a booster vaccine (58.3%), with 2 receiving Pfizer/BioNTech BNT162b2 (28.6%)
189	and 5 receiving Moderna mRNA-1273 (71.4%). Three of the participants who opted for a Moderna
190	mRNA-1273 booster received a half dose (i.e., 50 mcg vs. 100 mcg).
191	
192	Breakthrough Infection Characteristics
193	All breakthroughs described above were classified as mild, given the limited symptoms and lack of
194	medical intervention or hospitalization. As seen in Table 3, the most frequently reported symptoms
195	were cough (66.6%) and congestion/rhinorrhea (66.6%). Sore throat (41.6%) and headache (41.6%)
196	were also highly reported. Only one participant reported no symptoms. No participant reported
197	nausea, vomiting, or dyspnea.
198	
199	Assay Results
200	As shown in Table 4, all participants had detectable antibodies (discrete titers) with the Mount Sinai
201	assay all had detectable antibodies (BAU/ml) with the VITROS assay (Figure 1). Titers ranged from 1:800
202	to 1:51,200 for the Mt. Sinai assay (median: 1:19200; range: 1:800-51200) and from 57.4 to 13,500
203	BAU/ml for the VITROS assay (median: 2710; range: 103 – 13500). The cPass RBD-ACE2 interaction
204	inhibition assay showed 10/12 (83.3%) participants had positive surrogate neutralizing activity (SNA)
205	with 2/12 (16.7%) lacking SNA (<30%) as determined by manufacturer specifications. Among those
206	participants with positive surrogate neutralizing activity, $8/10$ had $98\%$ SNA, and two individuals had

- 207 90% SNA and 58% SNA respectively. Notably, the two individuals found negative for SNA were also
- 208 found to have lower values for the binding assays (i.e., Mount Sinai and VITROS).

210 The Icahn School of Medicine at Mount Sinai and the Ortho-Clinical VITROS Assay Correlate Well and

211 Quantitatively Agree

212 The participants' log-transformed, pre-breakthrough antibody titers ranged from 2.90 to 4.71. Bland-213 Altman analysis demonstrated good agreement between assays, as shown in Figure 2. The mean 214 difference was 0.91, with a 95% confidence interval of 0.527 to 1.285. Additionally, we found that the 215 Mount Sinai Laboratory assay endpoints were strongly correlated with the Ortho-Clinical VITROS assay 216 endpoints (Pearson correlation of r(10) = .99, p = <0.00001). We also examined the correlation between 217 the Mount Sinai Laboratory assay and the cPass assay, and found that the two assays were positively 218 associated (Pearson correlation of r(10) = .69, p = 0.013), though this was to a lesser degree than the 219 VITROS assay. 220 221 We designated the participants based on the number of SARS-CoV-2 "antigenic challenges" they have 222 experienced (i.e., vaccination and/or natural infection). After review of the variation in combinations 223 between natural infection and vaccination, individuals with only two SARS-CoV-2 "antigenic challenges" 224 appeared to have lower antibody titers (or less reactivity) across all three assays, although there is no 225 clear relationship between the quantity of "antigenic challenges" and increased antibody titers. Those 226 who had received booster vaccinations had higher antibody titers than those who did not with the 227 exception of one participant who had received their 2nd dose within 90 days of the breakthrough 228 infection.

229

### 230 **DISCUSSION**

The goal of this study was to investigate the impact of binding antibody titers and RBD-ACE2 interaction
inhibition titers on Omicron breakthrough infections. The binding antibody assays (Mount Sinai
Laboratory and Ortho-Clinical VITROS) correlated and quantitatively agreed. Given that the Ortho-

234 Clinical VITROS assay is calibrated to the WHO standard, this finding adds additional validity to this and 235 future work, particularly when conducting comparisons across assays. We also found that higher 236 binding titers were generally suggestive of higher SNA, though unfortunately magnitude (percent 237 neutralization) alone was clearly an insufficient marker of protection in preventing breakthrough 238 infection for the cohort described above. Overall, our results indicate that the observation of high 239 binding titers or SNA to ancestral spike/RBD alone do not adequately confer protection from 240 breakthrough infection with the Omicron variant. In spite of a recent study [32] suggesting adequate 241 viral neutralizing activity following booster vaccination, this study provides compelling evidence in a 242 longitudinal cohort that despite robust detection of antibody levels against the ancestral-strain by three 243 distinct assays, this does not establish proof of sufficient protection against antigenically distant 244 variants. 245 246 In this study, we have compared three distinct antibody assays in a vaccinated and/or boosted 247 population of suspected Omicron breakthrough cases. This work has several limitations, principally the 248 small sample size and variable immune experience of the cohort. Further, as is the case for the majority 249 of the available antibody assays, the Mount Sinai Laboratory assay and the cPass assay have not yet 250 been calibrated to the WHO standard. Our study does provide evidence for a correlation between the 251 Mount Sinai Laboratory and Ortho-Clinical VITROS assays, however. We believe that further 252 standardization of the serological assays to an international standard will allow better correlations of 253 immunity between independent clinical trials. 254 255 Finally, this study examined only samples immediately prior to breakthrough infection so factors 256 regarding temporal relationship of infection, clinical presentation, and sample collection may have 257 affected our observations. Additional studies including individuals who appear to be susceptible to re-

infection or who are poor immunologic responders to SARS-CoV-2 infection and/or vaccination, are
needed to better understand differential immune kinetics in those populations. Of particular interest
will be characterizing the T-cell immune responses to SARS-CoV-2 in individuals who have developed
strong antibody responses yet experience breakthrough infection. Importantly, since we did not
compare the titers of breakthrough cases with titers of non-breakthrough cases, we cannot draw
conclusions regarding where these titers would fall and if they trend lower than those of individuals who

265

266 Although mounting evidence suggests that both primary vaccination and boosters lessen the likelihood 267 of symptomatic infection, hospitalization and death following infection with Omicron, there remains an 268 urgent need for updated variants-specific an ultimately "variant-proof" vaccines and early treatment 269 modalities. This work has also highlighted the need for large-scale harmonization across serological 270 assays, particularly those that have low barriers for use (e.g., low cost, time-efficient), and that can be 271 scaled expediently to the population level. Further, COVID-19 severity, particularly in the case of 272 breakthrough infections, is related to antigen-specific adaptive immune responses [33-36], though the 273 precise mechanisms for individual susceptibility to breakthrough infections remain unclear. In addition 274 to greater clarification on the specifics of the humoral response to infection and vaccination is needed – 275 especially the role of mucosal antibodies and non-neutralizing antibodies. Future work should 276 incorporate profiling of cellular immunity to better define the immune landscape amongst diverse 277 populations affected by SARS-CoV-2 and its variants.

### 278 Funding

- 279 This work was partly funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC)
- contract 75N93019C00051 as part of the PARIS/SPARTA studies.
- 281

#### 282 Acknowledgements

- As ever, we are grateful to our research participants for their samples, time, and interest in this work.
- 284 At the University of Miami Miller School of Medicine, we thank Margaret Roach, Elizabeth Varghese, and
- the entire phlebotomy team at the Clinical Translational Research Site. We would also like to thank the
- 286 SARS-CoV-2 serology team at the Icahn School of Medicine at Mount Sinai, including Dominika Bielak
- and Gagandeep Singh.
- 288

### 289 Conflicts of Interest

- 290 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2
- serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and
- 292 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020)
- 293 which list Florian Krammer as co-inventor. Patent applications were submitted by the Icahn School of
- 294 Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for
- 295 SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently
- 296 consulting for Pfizer, Third Rock Ventures, Merck, Seqirus and Avimex. The Krammer laboratory is also
- collaborating with Pfizer on animal models of SARS-CoV-2.

- All other authors declare that they have no known competing financial interests or personal
- relationships that could have appeared to influence the work reported in this paper.
- 301

302		Works Cited
303 304	1.	CDC. Variant Proportions. 2022 1/15/2022; Available from: <u>https://covid.cdc.gov/covid-data-</u>
305 306	2.	<u>tracker/#variant-proportions</u> . Shiehzadegan, S., et al., <i>Analysis of the Delta Variant B.1.617.2 COVID-19</i> , Clinics and Practice.
307	_	2021. <b>11</b> (4): p. 778-784.
308 309	3.	Walls, A.C., et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020. <b>181</b> (2): p. 281-292.e6.
310 311	4.	McCallum, M., et al., Structural basis of SARS-CoV-2 Omicron immune evasion and receptor
312	5.	Carreño, J.M., et al., Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
313	_	Nature, 2021.
314 315	6.	Cameroni, E., et al., <i>Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic</i> shift. Nature, 2021.
316 317	7.	Cao, Y., et al., Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
318	8.	Liu, L., et al., Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2.
319		Nature, 2021.
320 221	9.	Servellita, V., et al., Neutralizing immunity in vaccine breakthrough infections from the SARS-
321	10	Dimercian Control and Delia Variants. Cell, 2022.
323	10.	Journal of infection, 2022; p. S0163-4453(22)00060-3.
324	11.	FDA. In Vitro Diagnostic EUAs - Serology and Other Adaptive Immune Response Tests for SARS-
325		CoV-2. 2022 1/24/2022; Available from: https://www.fda.gov/medical-devices/coronavirus-
326		disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-
327		euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2.
328	12.	Tan, C.W., et al., A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated
329		blockage of ACE2-spike protein-protein interaction. Nature Biotechnology, 2020. <b>38</b> (9): p. 1073-
330	12	1078. Earle K.A. et al. Evidence for antibody as a protective correlate for COVID 19 vaccines. Vaccine
332	15.	
333	14.	Gilbert, P.B., et al., Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy
334		clinical trial. Science, 2021: p. eab3435.
335	15.	Goldblatt, D., et al., Towards a population-based threshold of protection for COVID-19 vaccines.
336		Vaccine, 2022. <b>40</b> (2): p. 306-315.
337	16.	Khoury, D.S., et al., <i>Neutralizing antibody levels are highly predictive of immune protection from</i>
338	47	symptomatic SARS-CoV-2 infection. Nature Medicine, 2021. <b>27</b> (7): p. 1205-1211.
339	17.	Cromer, D., et al., Neutralising antibody titres as predictors of protection against SARS-Cov-2
340 371	10	For the KA set of Evidence for antibody as a protective correlate for COVID 19 vaccines Vaccine
342	10.	2021. <b>39</b> (32): p. 4423-4428.
343	19.	Steensels, D., et al., Comparison of SARS-CoV-2 Antibody Response Following Vaccination With
344		<i>BNT162b2 and mRNA-1273.</i> JAMA, 2021. <b>326</b> (15): p. 1533-1535.
345	20.	Feng, S., et al., Correlates of protection against symptomatic and asymptomatic SARS-CoV-2
J / L		
340 247	21	<i>infection.</i> Nature Medicine, 2021. <b>27</b> (11): p. 2032-2040.

349 22. Gilbert, P.B., et al., Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy 350 clinical trial. Science, 2022. 375(6576): p. 43-50. 351 23. Xia, H., et al., Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine. 352 bioRxiv, 2022: p. 2022.01.21.476344. 353 24. Gruell, H., et al., mRNA booster immunization elicits potent neutralizing serum activity against 354 the SARS-CoV-2 Omicron variant. Nature Medicine, 2022. 355 GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit. Instructions for Use; Version 25. 356 6.0: [Available from: https://www.fda.gov/media/143583/download. 357 26. VITROS. VITROS Anti-SARS-CoV-2 IgG Quantitative. Instructions for Use; Version 1.0: [Available 358 from: https://www.fda.gov/media/150675/download. 359 27. Amanat, F., et al., A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature 360 Medicine, 2020. 26(7): p. 1033-1036. 361 Stadlbauer, D., et al., SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a 28. 362 Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol, 2020. 57(1): p. 363 e100. Wajnberg, A., et al., Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. 364 29. 365 Science, 2020. 370(6521): p. 1227-1230. 366 30. Stadlbauer, D., et al., Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. 367 Nature, 2021. 590(7844): p. 146-150. 368 31. Contestable, P.H., Brett; Gardner, Amanda, An Evaluation of Performance of the VITROS 369 Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Assay, in AABB Virtual Annual 370 Meeting. 2021: Virtual. 371 32. Wratil PR, S.M., Priller A, et al., Three exposures to the spike protein of SARS-CoV-2 by either 372 infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature 373 Medicine, 2022. 374 33. Juthani, P.V., et al., Hospitalisation among vaccine breakthrough COVID-19 infections. The 375 Lancet Infectious Diseases, 2021. 21(11): p. 1485-1486. 376 34. Haque, A. and A.B. Pant, Mitigating Covid-19 in the face of emerging virus variants, 377 breakthrough infections and vaccine hesitancy. Journal of Autoimmunity, 2022. **127**: p. 102792. 378 35. Brosh-Nissimov, T., et al., BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully 379 vaccinated hospitalized COVID-19 patients in Israel. Clinical Microbiology and Infection, 2021. 380 **27**(11): p. 1652-1657. 381 36. Christensen, P.A., et al., Signals of Significantly Increased Vaccine Breakthrough, Decreased 382 Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused 383 by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. 384 Am J Pathol, 2022. 192(4): p. 642-652.



Figure 1: The Mount Sinai Laboratory Assay and the Ortho Clinical VITROS Assay are strongly correlated

Discrete antibody titers from the Mount Sinai Laboratory assay and binding antibody units (BAU/ml) from the Ortho Clinical VITROS assay were log-transformed prior to analysis. The assays were strongly correlated (t = 19, Pearson's r = 0.99, 95% Cl = 0.949 – 0.996; p = <0.001). The grey shaded area indicates the standard error margins.



Figure 2: The Mount Sinai Laboratory Assay and the Ortho Clinical VITROS Assay quantitatively agree

A Bland-Altman plot was generated in order to describe agreement between the Mount Sinai Laboratory assay and the Ortho Clinical VITROS assays. The y-axis demonstrates the difference between paired, logtransformed measurements (i.e., discrete AB values from the Mount Sinai vs. BAU from the Ortho Clinical VITROS assay) for each participant. The x-axis represents the average of the log-transformed measurement from each assay. The mean difference (0.91) between values is indicated by the black line, while the red dotted line represents the 95% confidence interval limits (0.527 – 1.285) for the average difference between assays. All data points fell within the limits of agreement, indicating good agreement between the assays.

## Table 1: Selected characteristics of the SARS-CoV-2 serological assays per laboratory or manufacturer specifications

	Mount Sinai 2-Step ELISA [27, 28, 30]	GenScript cPass [25]	Ortho-Clinical VITROS [26, 31]		
Assay type	ELISA/binding	ELISA/blocking	Solid phase/binding		
Antigen(s) used	RBD + recombinant full- length spike	RBD	Spike S1 domain		
Antibody class detected	lgG	Total (IgG/M/A)	lgG		
Units of detection	Discrete dilution titers or continuous area under the curve values <sup>b</sup>	Percent surrogate neutralization activity (<30%, 30-100%)*	Binding antibody units/ml (BAU/ml)		
Specificity (95% Cl)	100%ª	100%ª	100% (99.3-100.0%)		

RBD = receptor binding domain

<sup>a</sup> Cl not provided

<sup>b</sup> AUC values were not included in this analysis

n	12		
Gender (M/F)	6 (50%), 6 (50%)		
Age (Range)	50.5 (30-78)		
Race			
White	10 (83.3%)		
Black/African American	1 (8.3%)		
Other	1 (8.3%)		
Ethnicity			
Hispanic	4 (33.3%)		
Not Hispanic	8 (66.6%)		
COVID-19 Status at Study Entry			
Positive	6 (50%)		
Negative	6 (50%)		
Vaccine Manufacturer (Dose 1 + 2)			
n	12 (100%)		
Pfizer/BioNTech BNT162b2	8 (66.7%)		
Moderna mRNA-1273	3 (25%)		
Johnson & Johnson	1 (8.3%)		
Ad26.COV2.S			
Median Days Since 2 <sup>nd</sup> Dose to	172 (90-357)		
Breakthrough (Range) <sup>1</sup>			
Vaccine Manufacturer (Dose 3)			
n	7 (58.3%)		
Pfizer/BioNTech BNT162b2	2 (28.6%)		
Moderna mRNA-1273 <sup>2</sup>	5 (71.4%)		
Median Days Since 3 <sup>rd</sup> Dose to	61 (47-148)		
Breakthrough (Range) <sup>3</sup>			
Median Days From Pre-Breakthrough	31.5 (11-86)		
Sample Collection to Breakthrough			
(Range)			
Symptomatic Breakthrough	11 (91.7%)		
1 to design a second provide the second state of the second	fallouting Dags 2 suggestions		

<sup>1</sup> Individuals with breakthrough infection following Dose 3 were not included
 <sup>2</sup> Three individuals received half dose boosters (i.e., 50 mcg booster dose vs. 100 mcg for primary doses)
 <sup>3</sup> Individuals with breakthrough infection following Dose 2 were not included

			Congestion					Upset Stomach	Nausea			
Participant	Cough	Fever	Runny Nose	Sore Throat	Dyspnea	Anosmia	Dysgeusia	Diarrhea	Vomiting	Fatigue	Myalgias	Headache
<b>1</b> <sup>a</sup>												
2		Х		Х		Х	Х				Х	
3	Х		Х	Х		Х	Х					
4	Х		Х					Х			Х	Х
5 <sup>b</sup>		Х	Х							Х	Х	Х
6 <sup>b</sup>	Х	Х		Х								
7 <sup>b</sup>	Х		Х									
8 <sup>b</sup>	Х		Х					Х		Х		
9 <sup>b</sup>	Х	Х										
10	Х		Х	Х								Х
11 <sup>b</sup>			Х	Х						Х	Х	Х
12 <sup>b</sup>	Х		Х							Х		Х
n=12	8 (66.6%)	4 (33.3%)	8 (66.6%)	5 (41.6%)	0 (0%)	2 (16.6%)	2 (16.6%)	2 (16.6%)	0 (0%)	4 (33.3%)	4 (33.3%)	5 (41.6%)

### Table 3: Symptoms Reported During Omicron Breakthrough Infection

<sup>a</sup> Asymptomatic; no symptoms reported and was found to be positive after positive exposure

<sup>b</sup> Received a booster vaccination

			Days Between Pre- Breakthrough			
Participant	# of SARS-CoV-2 Cha and Vaccines	llenges (Infection(s) s) Prior to BT	Sample and Last Positive NAAT Test	lcahn SOM at Mt. Sinai Assayª	cPass Assay <sup>b</sup>	Ortho-Clinical VITROS <sup>c</sup>
1	3	NI, V2	75	51200	98, POS	6600
2	2	UI, V2	33	800	<30, NEG	57.4
3	2	UI, V2	16	1600	58, POS	103
4 <sup>f</sup>	3	NII, V1	11	1600	90, POS	116
5 <sup>d</sup>	3	UI, V3	27	51200	98, POS	6160
6 <sup>d</sup>	3	UI, V3	70	51200	98, POS	7490
7 <sup>d,e</sup>	4	NI, V3	23	12800	98, POS	2250
8 <sup>d,e</sup>	4	NI, V3	36	25600	98, POS	2710
9 <sup>d</sup>	3	UI, V3	86	51200	98, POS	13500
10	3	NI, V2	33	6400	<30, NEG	635
11 <sup>d,e</sup>	4	NI, V3	30	25600	98, POS	4890
12 <sup>d</sup>	3	UI, V3	19	6400	98, POS	1210

### Table 4: Mt. Sinai Laboratory, Ortho-Clinical VITROS, and Genscript cPASS Assay Results

UI = No hx of natural infection prior to BT; NI = Hx of natural infection prior to BT; NII: Hx of natural infection 2x prior to BT; V1 = Vaccinated once; V2 = Vaccinated twice; V3 = Vaccinated twice + booster vaccination; BT = Breakthrough infection

<sup>a</sup> Discrete antibody titers may be reported from 1:100-204,800, though in this study discrete titers were only observed up to 51,200.

<sup>b</sup> Surrogate neutralizing activity was reported from <30 – 100% (< 30% = Neg, 30 – 100% = Pos)

<sup>c</sup> Undiluted linear range 2 – 200 BAU/ml, samples diluted as needed to achieve result in linear range of 2-200 BAU/ml

<sup>d</sup> Received a booster vaccination

<sup>e</sup> Received a Moderna mRNA-1273 half dose

<sup>f</sup> Received Johnson & Johnson Ad26.COV2.S as primary vaccination